Table 5 Summary of treatment characteristics (During follow up)

Mediator release treatment

n (%)

 Antihistamine (H1 blocker)

98 (94.23%)

 H2 blocker

96 (92.30%)

 Montelukast

12 (11.54%)

 Omalizumab

11 (10.58%)

Cytoreductive treatment

n (%)

 IFN

6 (5.77%)

  SD

4 (66.7%)

  PD

2 (33.3%)

 Cladribine

9 (8.65%)

  SD

4 (44.5%)

  PR

2 (22.2%)

  CI

3 (33.3%)

 Imatinib^b

5 (4.81%)

  SD

3 (60.0%)

  PD

1 (20.0%)

 Dasatinib

2 (1.92%)

  SD

2 (100.0%)

 Midostaurin

17 (16.35%)

  CI

9 (52.94%)

  PR

8 (47.06%)

 Azacitidine^a

1 (0.96%)

 Avapritinib

1 (0.96%)

  CI

1 (100.00%)

 Allogeneic stem cell transplantation

4 (3.85%)

 0

79 (75.96%)

 1

9 (8.65%)

 2

7 (6.73%)

 3

6 (5.77%)

 4

1 (0.96%)